SCHEMBL6823591

SCHEMBL6823591

COC(=O)C(C)(C)C(CCCCc1ccccc1)OS(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP24A1 Q07973 1/20 0.46
▸ PDE4A P27815 6/20 0.43
▸ PDE4B Q07343 6/20 0.43
▸ PDE4C Q08493 6/20 0.43
▸ PDE4D Q08499 6/20 0.43
▸ MMP1 P03956 5/20 0.43
▸ MMP2 P08253 5/20 0.43
▸ MMP3 P08254 5/20 0.43
▸ PTPRC P08575 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPRB P23467 1/20 0.42
▸ PTPRG P23470 1/20 0.42
▸ ACP1 P24666 1/20 0.42
▸ PRSS1 P07477 2/20 0.41
▸ CTSG P08311 2/20 0.41
▸ CTRB1 P17538 2/20 0.41
▸ CMA1 P23946 2/20 0.41
▸ FAAH O00519 1/20 0.41
▸ POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823189 0.79 TRPA1 (0.49) MMP2MMP3PRSS1CTSGCTRB1
SCHEMBL6819821 0.74 MMP1 (0.61) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL8133260 0.72 CTSG (0.47) PRSS1CTSGCTRB1CMA1FAAH
SCHEMBL16414222 0.72 CTRB1 (0.52) MMP2PRSS1CTSGCTRB1CMA1
SCHEMBL6823006 0.71 MEN1 (0.44) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL6819932 0.71 PDE4A (0.63) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL27500518 0.70 PTPN2 (0.51) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL8617083 0.70 POLB (0.46) CYP24A1PDE4APDE4BPDE4CPDE4D
SCHEMBL13198523 0.70 ATM (0.48) —
SCHEMBL6823465 0.70 MMP1 (0.47) PDE4APDE4BPDE4CPDE4DMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0871439-B1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS AVENTIS PHARMA INC (US) 2004-03-31 — — EP disclosed
US-6057369-A USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-05-02 — — US disclosed
EP-0871439-A4 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE POULENC RORER PHARMA (US) 1999-07-21 — — EP disclosed
EP-0871439-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1998-10-21 — — EP disclosed
WO-1997024117-A1 SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-10 — — WO disclosed
Send feedback